GlaxoSmithKline

GlaxoSmithKline plc (LSE: GSK NYSE: GSK), often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's third largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer). It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions. It also has a large consumer healthcare division which produces and markets oral healthcare products, nutritional drinks and over-the-counter medicines, including Sensodyne, Horlicks and Gaviscon.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's May 31, 2012 filing.
Download all contributions to GlaxoSmithKline

  • Summary

    overview of the committee's finances
    Total Raised:
    $811,356
    Total Spent:
    $867,891
    Cash on Hand:
    $48,762
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars. "Other" includes 3rd parties and organizations without official party affiliation.

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for GlaxoSmithKline Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$4,415,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of GlaxoSmithKline

View all lobbying data for GlaxoSmithKline Sources: Lobbyist Registration Tracker OpenSecrets.org

Regulations

27 Mentions; 4 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "GlaxoSmithKline" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
    • Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
    • Toggle 1 FDA Draft Guidance for Industry on Non-Penicillin Beta-Lactam Risk Assessment: A CGMP Framework; Availability 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 5 FDA Advisory Opinion regarding certain drug delivery device patents submitted for listing in the Orange Book under Section 505 of the Federal Food, Drug, and Cosmetic Act 2011
    • Toggle 5 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2011
    • Toggle 3 FDA To Declare That the Product Ondansetron Effervescent Tablets 8 mg is Suitable for Submission as an Abbreviated New Drug Application (ANDA) 2011
    • Toggle 3 CMS Hospital Outpatient Prospective Payment; Ambulatory Surgical Center Payment; Hospital Value-Based Purchasing Program; Physician Self-Referral; and Provider Agreement Regulations on Patient Notification Requirements 2011
    • Toggle 2 FDA Ban Both The Prescription Drug, Xenical (orlistat) And The Over-the-Counter Alli (orlistat) Because They Expose Patients to Serious Risks 2011
    • Toggle 2 FDA Periodic Review of Existing Regulations; Retrospective Review Under Executive Order 13563 2011
    • Toggle 2 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
    • Toggle 1 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Examination of Online Direct-to-Consumer Prescription Drug Promotion 2011
    • Toggle 1 CMS Medicare & Medicaid: Influenza Vaccination Standard for Certain Medicare & Medicaid Participating Providers and Suppliers 2011
    • Toggle 1 FTC Early Terminations of Waiting Periods under Premerger Notification Rules 2011

Federal Spending

4 contracts
Information

Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.

Only grants, contracts and loans with amounts over $1 million are shown.

Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.

covers through USASpending.gov's March 1, 2012 release

Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.

Type Recipient Name Year Agency Description Amount
contract
 Glaxosmithkline Llc 2011 Office Of Assistant Secretary For Management And Budget RESEARCH AND DEVELOPMENT FACILITIES $38,506,842
contract
 Glaxosmithkline Llc 2012 Centers For Disease Control GSK 2011 VFA $7,464,818
contract
 Glaxosmithkline Llc 2011 Centers For Disease Control GSK 2011 VFA $5,442,235
contract
 Glaxosmithkline Llc 2011 Centers For Disease Control GSK 2011 VFA $4,843,178
View all grant & loan data for GlaxoSmithKline View all contract data for GlaxoSmithKline Sources: USASpending.gov

Contractor Misconduct

9 Instances
Information

This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.

More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.

covers through POGO's March 3, 2012 release
Misconduct Type Hired By Incident Year Disposition Penalty
Health None Puerto Rico Drug Manufacturing Facility Settlement: State AGs 2011 Settlement $40,750,000
Antitrust None Defrauding Louisiana's Medicaid Program 2012 Settlement $10,000,000
Intellectual Property None Nigeria Trademark Infringement 2011 Judgment Against Defendant $7,873,706
Antitrust None South Korea Antitrust Fine 2011 Fine $2,651,737
Health None Argentina Vaccine Trials Fine 2012 Fine $93,000
Health None 2011 Criminal and Civil Investigations Settlement 2011 Settlement $0
Health None Current Good Manufacturing Practice Violations at Worthing, UK Facility 2011 Investigative Finding $0
Health None Louisiana Attorney General Avandia Lawsuit 2011 Pending $0
Health None South Carolina Attorney General Avandia Lawsuit 2011 Pending $0
View all contractor misconduct data for GlaxoSmithKline Sources: Federal Contractor Misconduct Database from POGO

Advisory Committees

3 people on 3 committees
Information

Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.

The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.

covers through 2011

Table shows employees of "GlaxoSmithKline" that sat on federal advisory committees.

  • Agency
  • Representation
  • Toggle Department of Health and Human Services 2 people on 2 committees
  • Toggle Environmental Protection Agency 1 person on 1 committee
View all advisory committee data for GlaxoSmithKline